source
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
- U.S. loses measles elimination status as outbreaks claim first deaths in decadesThe Pan American Health Organization announced that the United States has lost its measles elimination status, a designation it held for 26 years. The decision follows a year‑long period of sustain…